These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 33554872

  • 1. Immune Checkpoint Inhibitor-Induced Adrenalitis and Primary Adrenal Insufficiency: Systematic Review and Optimal Management.
    Shi Y, Shen M, Zheng X, Yang T.
    Endocr Pract; 2021 Feb; 27(2):165-169. PubMed ID: 33554872
    [Abstract] [Full Text] [Related]

  • 2. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
    Grouthier V, Lebrun-Vignes B, Moey M, Johnson DB, Moslehi JJ, Salem JE, Bachelot A.
    Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
    [Abstract] [Full Text] [Related]

  • 3. Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects.
    Martella S, Lucas M, Porcu M, Perra L, Denaro N, Pretta A, Deias G, Willard-Gallo K, Parra HS, Saba L, Scartozzi M, Wekking D, Kok M, Aiello MM, Solinas C.
    Semin Oncol; 2023 Dec; 50(6):144-148. PubMed ID: 38151399
    [Abstract] [Full Text] [Related]

  • 4. American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach.
    Yuen KCJ, Samson SL, Bancos I, Gosmanov AR, Jasim S, Fecher LA, Weber JS.
    Endocr Pract; 2022 Jul; 28(7):719-731. PubMed ID: 35477029
    [Abstract] [Full Text] [Related]

  • 5. Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS.
    Lu D, Yao J, Yuan G, Gao Y, Zhang J, Guo X.
    J Endocrinol Invest; 2022 Nov; 45(11):2131-2137. PubMed ID: 35870109
    [Abstract] [Full Text] [Related]

  • 6. Nivolumab-induced adrenalitis.
    Iqbal I, Khan MAA, Ullah W, Nabwani D.
    BMJ Case Rep; 2019 Dec 01; 12(11):. PubMed ID: 31791986
    [Abstract] [Full Text] [Related]

  • 7. Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event.
    Deligiorgi MV, Trafalis DT.
    Int Immunopharmacol; 2020 Dec 01; 89(Pt B):107050. PubMed ID: 33069924
    [Abstract] [Full Text] [Related]

  • 8. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y, Ye X, Hu F, Xu J, Guo X, Zhuang Y, He J.
    J Immunother Cancer; 2019 Nov 06; 7(1):286. PubMed ID: 31694698
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Endocrine side effects of immune checkpoint inhibitors.
    Cardona Z, Sosman JA, Chandra S, Huang W.
    Front Endocrinol (Lausanne); 2023 Nov 06; 14():1157805. PubMed ID: 37251665
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis.
    Lu J, Li L, Lan Y, Liang Y, Meng H.
    Cancer Med; 2019 Dec 06; 8(18):7503-7515. PubMed ID: 31679184
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review.
    Yang Y, Liu J, Yang K, Ma Y, Fu S, Tang X, Wang Y, Zhou L.
    J Clin Pharmacol; 2021 Mar 06; 61(3):282-297. PubMed ID: 33345342
    [Abstract] [Full Text] [Related]

  • 20. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
    Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST.
    JAMA Dermatol; 2022 Aug 01; 158(8):933-941. PubMed ID: 35612829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.